News

The recalls have been classified as Class II, where the probability of serious adverse health consequences is remote.
As the HHS and FDA leadership continues to look for ways to boost transparency and reshape the United States' healthcare ...
With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...
The FDA classifies this recall as Class II, which the agency describes as a situation "in which use of or exposure to a ...
System integrates glucose biosensor with an AI-driven platform to show how food, activity, stress, sleep affect the body in ...
The FDA has broadened the indication for evolocumab (Repatha; Amgen) to include adults at increased risk of major adverse ...